[June 23, 2015]

Research and Markets: Mild Psoriasis Therapeutics Pipeline Review, H1 2015 - 8 Companies & 10 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/gz43q8/mild_psoriasis) has announced the addition of the "Mild Psoriasis - Pipeline Review, H1 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Mild Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic developmet for Mild Psoriasis and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies Involved in Therapeutics Development

• Almirall, S.A.
• Avexxin AS
• Convoy Therapeutics, Inc.
• Delenex Therapeutics AG
• GlycoMar Limited
• OPKO Health, Inc.
• Soligenix, Inc.
• UCB S.A.

Drug Profiles

• AKP-11
• AVX (News - Alert)-001
• cyclosporine
• DLX-105
• DLX-3003
• GLY-2028
• lunacalcipol
• SGX-301
• tazarotene
• UCB-5857

For more information visit http://www.researchandmarkets.com/research/gz43q8/mild_psoriasis

View source version on businesswire.com: http://www.businesswire.com/news/home/20150623006130/en/

[ Back To TMCnet.com's Homepage ]